Feature | March 24, 2014

Sorin Acquires Oscor’s CRM Lead Business for MRI Compatible Standard Systems

Acquisition will allow Sorin to respond better to the rapidly changing market conditions, requiring high-quality value-driven MRI compatible standard systems

March 24, 2014 — Sorin Group has purchased Oscor Inc. lead business, including a lead manufacturing facility in the Dominican Republic for a value of approximately $20 million.

Oscor, headquartered in Tampa Fla., is one of the largest independent players in the development and manufacture of cardiac leads and catheters. With more than 400 employees and manufacturing facilities in the United States and the Dominican Republic, Oscor sells its products both to end-customers and to leading medical device companies, including Sorin Group, on an original equipment manufacturer (OEM) basis.

Under this agreement, Sorin Group acquires: 1) Oscor-branded and OEM for Sorin bradycardia lead business; 2) design files and development resources which will be the foundation for the development of magnetic resonance imaging (MRI) compatible tachycardia and left ventricular leads; and 3) one of Oscor’s fully equipped lead manufacturing facilitues, ISO certified and FDA registered, based in the Dominican Republic.

Sorin Group expects this acquisition will generate additional revenues from Oscor’s existing lead business and consolidate its MRI-compatible brady leads that are currently produced by Oscor. In addition, this agreement represents an opportunity for further co-operative development with Oscor of brady and tachy leads that will accommodate upcoming market requirements for MRI.

The transaction is subject to customary closing conditions.

For more information: www.sorin.com

Related Content

EpiAccess System, EpiEP, Mount Sinai New York, epicardial access
News | Ablation Systems| August 22, 2016
August 22, 2016 — The Mount Sinai Hospital is the first site in the New York metropolitan area to pioneer a new appro
warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney
News | Antiplatelet and Anticoagulation Therapies| August 16, 2016
August 16, 2016 — Warfarin prescribed to prevent strokes in...
Sponsored Content | Videos | Inventory Management| August 15, 2016
Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a chall
News | EP Lab| August 12, 2016
August 12, 2016 — Electrophysiology ablation navigation system company Stereotaxis Inc.
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders| August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in th
pros and cons of new anticoagulation therapies, anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies| July 26, 2016 | Heidi Olson, Pharm.D
With the recent introduction of several novel oral...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init